fashion -WSS

fashion

author：fashion 2025-09-30 16:23:25 - browse：3

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Vir antibody drug aimed at influenza A fails in clinical trial

knowledge

WSS

Precocious puberty in girls comes with mental health risks

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

First medicine developed to treat MASH expected to be approved soon

The drug industry has found itself all alone in Washington

Affordable Connectivity Program vital to health care, experts say

The Readout: Amylyx, Alumis, and Lundbeck drug updates

hotspot

fashion

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Judge rejects Trump's request to move Stormy Daniels hush

At least 13 dead in Texas as scorching temps continue

Indian pharmaceutical industry in denial over drug

ChatGPT in medicine: STAT answers readers' burning questions

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Moonlake's readout produced a cash windfall. Risks remain

Amylyx ALS drug failure raises questions and concerns

Continuity nursing helped my family in our darkest PICU moments

Tocagen's brain cancer gene therapy trial continues. Investors worry

explore

First medicine developed to treat MASH expected to be approved soon

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Headspace, Meta partner to launch VR meditation app for Quest

DeSantis talks Trump, trans issues and 'what wokeness is'

DeSantis talks Trump, trans issues and 'what wokeness is'

hotspot

knowledge

knowledge

hotspot